Exhibit 99.1 Hyperfine, Inc. Reports First Quarter 2024 Financial Results GUILFORD, Connecticut, May 13, 2024 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2024 financial results and provided a business update. "We have kicked off 2024 strong. I am pleased with our commercial progress shown by sales ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Hyperfine, Inc. (HYPR) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 13, 2024, might help the stock move higher if these key numbers are better than exp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number: 001-39949 Hyperfine, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 98-1569027 (I.R.S. Employer Identification No.) 351 New Whitfield Street Guilford, Connecticut 06437 (Address o ...

Hyperfine, Inc. (NASDAQ:HYPR) Q4 2023 Earnings Conference Call March 21, 2024 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Maria Sainz - President and Chief Executive Officer Brett Hale - Chief Administrative Officer and Chief Financial Officer Conference Call Participants Yuan Zhi - B. Riley Operator Thank you for standing by, and welcome to the Hyperfine Fourth Quarter 2023 and Fiscal Year 2023 Earnings Conference Call. At this time, all participants are in a listen-o ...

Hyperfine, Inc. (NASDAQ:HYPR) Q3 2023 Earnings Call November 9, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations Maria Sainz - President and Chief Executive Officer Brett Hale - Chief Administrative Officer and Chief Financial Officer Conference Call Participants Neil Chatterji - B. Riley Operator Good afternoon, and welcome to Hyperfine's Third Quarter 2023 Earnings Conference Call. Currently, all participants are in a listen-only mode. We will be facilitating a question-and-answer se ...

The Swoop system expands the fast growing (6% annual CAGR) $35 billion global imaging market. CONFIDENTIAL – PROPERTY OF HYPERFINE, INC. ©2023, All rights reserved. 10 Deep Foundation to Drive Long-term Success Rapid Innovation Clinical Proof Regulatory Excellence Ecosystem of Support 11 A First for Brain Health | --- | --- | |---------------------|----------------------------------------------------| | | | | | | | Hyperfine, Inc. has | | | 01 | reimagined brain imaging | | with the | Swoop system — | | | a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-Q _________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or Guilford, Connecticut 06437 (Address of principal executive offices) (Zip Code) Delaware 98-1569027 (IRS Employer Identification No.) (866) 796-6767 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...

Hyperfine Inc. (NASDAQ:HYPR) Q2 2023 Results Conference Call August 14, 2023 4:30 PM ET Company Participants Marissa Bych - IR Maria Sainz - CEO, President & Director Brett Hale - Chief Administrative Officer and CFO Conference Call Participants Neil Chatterji - B. Riley Operator Good afternoon. Welcome to Hyperfine Second Quarter 2023 Earnings Conference Call. Currently, all participants on a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a remin ...

Financial Performance - Device sales for the three months ended June 30, 2023, increased by $1.6 million, or 140.6%, compared to the same period in 2022, driven by strong international sales and higher sales prices [106]. - Total sales for the six months ended June 30, 2023, were $6.016 million, a 97.8% increase from $3.042 million in the same period of 2022 [106]. - The gross margin for the three months ended June 30, 2023, was $1.444 million, compared to a loss of $165, indicating a significant improvement in profitability [106]. - Service sales increased by $0.4 million, or 57.5%, for the six months ended June 30, 2023 compared to the same period in 2022, driven by an increase in the install base [108]. - Device sales increased by $2.6 million, or 109.4%, for the six months ended June 30, 2023 compared to the same period in 2022, attributed to higher sales volume and increased sales prices [108]. - The net loss for the three months ended June 30, 2023, was $10.637 million, a 54.1% reduction from a net loss of $23.159 million in the same period of 2022 [106]. - The company reported a net loss of $22.8 million for the six months ended June 30, 2023, with an accumulated deficit of $232.3 million as of the same date [124]. - The net loss for the six months ended June 30, 2023, was $22.8 million, compared to a net loss of $46.9 million for the same period in 2022 [131][132]. Expenses and Cost Management - Research and development expenses decreased by 31% to $10.792 million for the six months ended June 30, 2023, down from $15.599 million in the same period of 2022 [106]. - Operating expenses for the three months ended June 30, 2023, were reduced by 43% to $13.136 million compared to $23.027 million in the same period of 2022 [106]. - Research and development expenses decreased by $4.8 million, or 30.8%, for the six months ended June 30, 2023 compared to the same period in 2022, primarily due to reduced personnel and consulting costs [113]. - General and administrative expenses decreased by $11.9 million, or 50.8%, for the six months ended June 30, 2023 compared to the same period in 2022, driven by a reduction in personnel-related costs [116]. - Sales and marketing expenses decreased by $2.9 million, or 36.2%, for the six months ended June 30, 2023 compared to the same period in 2022, mainly due to lower personnel and marketing event costs [118]. - Total cost of sales increased by $294 thousand, or 9.4%, for the six months ended June 30, 2023 compared to the same period in 2022, with device sales costs rising by 14.1% [109]. Cash Flow and Financial Position - As of June 30, 2023, the company had cash and cash equivalents of $93.9 million, which is expected to support operations for at least the next 12 months [125]. - For the six months ended June 30, 2023, net cash used in operating activities was $23.2 million, a decrease from $44.2 million in the same period of 2022 [131][132]. - Net cash used in investing activities remained consistent at $0.3 million for both the six months ended June 30, 2023, and 2022, attributed to fixed asset purchases [133][134]. - Net cash provided by financing activities increased to $0.1 million in the first half of 2023 from $2,000 in the same period of 2022, primarily from option exercises [135][136]. - As of June 30, 2023, the company had $95 million in cash, cash equivalents, and restricted cash, primarily in money market funds and savings accounts [146]. Market and Product Development - The total installed base of the Swoop® system reached 131 units as of June 30, 2023, up from 92 units in the same period of 2022, representing a growth of 42.4% [97]. - The company received FDA clearance for the latest update of the Swoop® system software in February 2023, which significantly improves diffusion-weighted imaging (DWI) quality [94]. - The Swoop® system is positioned to expand the $32 billion imaging market by increasing access to MRI technology in various healthcare settings [91]. - The company has deployed 20 Swoop® system units to hospitals in low-middle income settings through funding from the Bill & Melinda Gates Foundation [104]. - The company received a $3.4 million grant from the BMGF in May 2023 to develop a scalable approach to measuring neurodevelopment in low-to-middle income countries, with $0.5 million received by June 30, 2023 [138]. Risks and Future Outlook - The company anticipates continued cash burn and net losses until product and service sales generate sufficient gross profit to cover operating expenses [124]. - A 0.5 percentage point decrease in interest rates would decrease earnings before income taxes by $0.5 million based on the balance sheet position at June 30, 2023 [146]. - Inflationary pressures may increase manufacturing costs, which could adversely affect the company's financial condition and results of operations [147]. - The company operates primarily in U.S. dollars and does not have significant exposure to foreign exchange risk [148].

Hyperfine, Inc. (NASDAQ:HYPR) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Maria Sainz - President, Chief Executive Officer Brett Hale - Chief Administrative Officer, Incoming Chief Financial Officer Marissa Bych - Investor Relations, The Gilmartin Group Conference Call Participants Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Neil Chatterji - B. Riley Operator At this time all participants are in listen-only mode. After the speakers presentation there will be a ...